Explore our materials

International Workshop on HIV & Hepatitis Co-infection 2017

HCV elimination program in Georgia: Successes and challenges | Nikoloz Chkhartishvili, MD, MS, PhD

International Workshop on HIV & Hepatitis Co-infection 2017

Antifibrotics and fatty liver drugs in the pipeline | Sanjay Bhagani, MD

International Workshop on HIV & Hepatitis Co-infection 2017

NASH and NAFLD in HIV: same or different? | Mariana Machado, MD

Marion Peters

International Workshop on HIV & Hepatitis Co-infection 2017

Non liver and survival benefits of SVR in HCV | Marion Peters, MD

International Workshop on HIV & Hepatitis Co-infection 2017

The use of HIV+ or HCV+ organs in transplantation | Stefano Fagiuoli, MD

Douglas Dieterich

International Workshop on HIV & Hepatitis Co-infection 2017

Are there any special populations in treatment of HCV left? | Douglas Dieterich, MD

David Back

PhD

International Workshop on HIV & Hepatitis Co-infection 2017

Pharmacologist's perspective | David Back, PhD

Charles Boucher

MD, PhD

International Workshop on HIV & Hepatitis Co-infection 2017

Virologist's perspective | Charles Boucher, MD, PhD

Kosh Agarwal

International Workshop on HIV & Hepatitis Co-infection 2017

Special considerations before / during / after DAA therapy | Kosh Agarwal, MD

International Workshop on HIV & Hepatitis Co-infection 2017

HBV cure: what is coming in 5 – 10 years? | Patrick Kennedy, MD

Jürgen Rockstroh

International Workshop on HIV & Hepatitis Co-infection 2017

EASL highlights 2017 | Jürgen Rockstroh, MD